News >

Selinexor Again Shows Promise in Heavily Pretreated Myeloma

Jason M. Broderick @jasoncology
Published: Tuesday, May 01, 2018

blood cells Selinexor induced an overall response rate (ORR) of 25.4% in patients with penta-refractory multiple myeloma, according to top-line results from part 2 of the phase IIb STORM trial reported by Karyopharm Therapeutics. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x